<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122394</url>
  </required_header>
  <id_info>
    <org_study_id>CDP 09-414</org_study_id>
    <nct_id>NCT01122394</nct_id>
  </id_info>
  <brief_title>Reducing Risk of Recurrence</brief_title>
  <acronym>RRR</acronym>
  <official_title>Reducing Risk of Recurrences: Issues in Maintenance and Stability in Stroke (CDA 08-009)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adults who have had a previous stroke or transient ischemic attack (TIA) remain at risk for
      having a second serious event, especially if they have uncontrolled blood pressure or
      cholesterol. However, many patients have difficulty following treatment recommendations for
      lowering blood pressure and cholesterol. The purpose of this research project is to evaluate
      the effect of 2 booster sessions of an educational counseling intervention on how well adults
      who have already participated in a 6-month clinical trial had a stroke or transient ischemic
      attack (TIA) are able to follow a treatment plan and control their blood pressure and
      cholesterol levels. We will also examine how effective this intervention is in improving
      adherence to diet, medication, and physical activity recommendations for adults who have had
      a prior stroke or TIA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      National recommendations state that patients with a history of transient ischemic attack
      (TIA) or ischemic stroke should receive hypertension treatment, including antihypertensive
      medication and lifestyle modification, with a goal of reducing blood pressure (BP) to &lt;120 mm
      Hg systolic BP and &lt;80 mm Hg diastolic BP. Statin treatment and lifestyle modification is
      also recommended for post-stroke and post-TIA patients with elevated cholesterol levels or a
      history of stroke or TIA with an atherosclerotic cause. Despite the clear benefits of
      secondary stroke prevention, there is a gap between evidence and implementation in clinical
      practice. We will determine whether a telephone-delivered behaviorally tailored intervention
      (TI) can lead to sustained change resulting in (a) BP and lipid control and (b) improved
      adherence to diet, medication, and exercise recommendations in veterans with a history of
      stroke or TIA compared to an attention placebo (AP) in veterans who have completed 6 months
      of a clinical trial. In this CDA project, we evaluate the long-term effectiveness of booster
      sessions in a randomized manner. One arm will receive 6 months of a tailored intervention
      (TI) followed by two booster TI sessions at 8 and 10 months, and one arm will receive 6
      months of an attention placebo (AP) followed by two booster AP sessions at 8 and 10 months.
      BP (3 measures taken at least 5 min apart) and dietary sodium are the primary outcomes, while
      secondary outcomes will be total cholesterol/high density lipoprotein ratio, adherence to
      antihypertensive and lipid-lowering drugs, and exercise adherence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary Sodium</measure>
    <time_frame>6 months</time_frame>
    <description>self-reported stage of change for adherence to DASH (low-sodium) diet. Pre-action refers to participants reporting that they were in pre-contemplation (no plans to adhere to DASH diet in the next 6 months), contemplation (planning to adhere within the next 6 months) or preparation (planning to adhere within the next month), while action refers to participants reporting that they are in the action stage of change (became adherent to the DASH diet within the past 6 months) and maintenance refers to participants reporting that they are in the maintenance stage of change (became adherent to the DASH diet at least 6 months ago)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol/High Density Lipoprotein Ratio</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by 7-day Physical Activity Recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive/ Lipid-lowering Medication Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by Morisky Medication taking questionnaire (self-reported). Scores range from 0-4, with 0 being least adherent and 4 being most adherent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Stroke</condition>
  <condition>TIA</condition>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Tailored Intervention (TI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored intervention based on the transtheoretical model</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention Placebo (AP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Attention Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TI</intervention_name>
    <description>Tailored intervention based on the transtheoretical model</description>
    <arm_group_label>Tailored Intervention (TI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>AP</intervention_name>
    <description>Attention placebo</description>
    <arm_group_label>Attention Placebo (AP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Well-documented history of stroke or TIA that occurred at least 3 months prior to
             enrollment;

          -  Age 21 years or older;

          -  Continuity of care in the VAMC primary care or neurology clinics, defined as at least
             1 visit in either clinic during the past 1 year;

          -  On hypertensive and/or lipid-lowering agents;

          -  A score of &gt;16 on the Mini-Mental Status Exam;

          -  ability to exercise (assessed by 6-minute walk or timed get up and go).

        Exclusion Criteria:

          -  Limited life expectancy due to a severe non-CVD related comorbid terminal illness such
             as cancer;

          -  No telephone number at which patient can be reached;

          -  Plans to relocate outside of the NYC area within the next 6 months;

          -  Inability to communicate over the telephone due to severe cognitive impairment or
             aphasia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer P Friedberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <results_first_submitted>July 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2016</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>recurrence</keyword>
  <keyword>blood pressure</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from a prior American Heart Association-funded study testing the effectiveness of a 6-mo TI vs. AP. Participants were recruited at completion of the AHA study to participate in the current study for an additional 6 months. They continued to receive the intervention to which they were originally assigned in the AHA study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tailored Intervention (TI)</title>
          <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
        </group>
        <group group_id="P2">
          <title>Attention Placebo (AP)</title>
          <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tailored Intervention (TI)</title>
          <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
        </group>
        <group group_id="B2">
          <title>Attention Placebo (AP)</title>
          <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.38" spread="9.86"/>
                    <measurement group_id="B2" value="68.73" spread="10.30"/>
                    <measurement group_id="B3" value="67.62" spread="10.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White (non-Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American (non-Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <time_frame>6 months</time_frame>
        <population>restricted to only patients enrolled because they met criteria for high blood pressure at enrollment. Participants were not included if they were did not have elevated blood pressure at enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Tailored Intervention (TI)</title>
            <description>Tailored intervention based on the transtheoretical model
TI: Tailored intervention based on the transtheoretical model</description>
          </group>
          <group group_id="O2">
            <title>Attention Placebo (AP)</title>
            <description>Attention Placebo
AP: Attention placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <population>restricted to only patients enrolled because they met criteria for high blood pressure at enrollment. Participants were not included if they were did not have elevated blood pressure at enrollment</population>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.83" lower_limit="119.5" upper_limit="144.83"/>
                    <measurement group_id="O2" value="133.67" lower_limit="114.5" upper_limit="144.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Robust regressions were performed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>robust regression</method>
            <method_desc>controlling for provider clustering</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dietary Sodium</title>
        <description>self-reported stage of change for adherence to DASH (low-sodium) diet. Pre-action refers to participants reporting that they were in pre-contemplation (no plans to adhere to DASH diet in the next 6 months), contemplation (planning to adhere within the next 6 months) or preparation (planning to adhere within the next month), while action refers to participants reporting that they are in the action stage of change (became adherent to the DASH diet within the past 6 months) and maintenance refers to participants reporting that they are in the maintenance stage of change (became adherent to the DASH diet at least 6 months ago)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tailored Intervention (TI)</title>
            <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
          </group>
          <group group_id="O2">
            <title>Attention Placebo (AP)</title>
            <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
          </group>
        </group_list>
        <measure>
          <title>Dietary Sodium</title>
          <description>self-reported stage of change for adherence to DASH (low-sodium) diet. Pre-action refers to participants reporting that they were in pre-contemplation (no plans to adhere to DASH diet in the next 6 months), contemplation (planning to adhere within the next 6 months) or preparation (planning to adhere within the next month), while action refers to participants reporting that they are in the action stage of change (became adherent to the DASH diet within the past 6 months) and maintenance refers to participants reporting that they are in the maintenance stage of change (became adherent to the DASH diet at least 6 months ago)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-action</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Action or Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Regression, Logistic</method>
            <method_desc>This analysis includes participants in pre-action and action/maintenance</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol/High Density Lipoprotein Ratio</title>
        <time_frame>6 months</time_frame>
        <population>Only participants who provided a blood sample for which cholesterol could be analyzed were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tailored Intervention (TI)</title>
            <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
          </group>
          <group group_id="O2">
            <title>Attention Placebo (AP)</title>
            <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol/High Density Lipoprotein Ratio</title>
          <population>Only participants who provided a blood sample for which cholesterol could be analyzed were included in this analysis</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" lower_limit="2.8" upper_limit="4.25"/>
                    <measurement group_id="O2" value="3.21" lower_limit="2.8" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Adherence</title>
        <description>Measured by 7-day Physical Activity Recall</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tailored Intervention (TI)</title>
            <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
          </group>
          <group group_id="O2">
            <title>Attention Placebo (AP)</title>
            <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Adherence</title>
          <description>Measured by 7-day Physical Activity Recall</description>
          <units>hours per week of cardio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.25" upper_limit="5.25"/>
                    <measurement group_id="O2" value="2.75" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antihypertensive/ Lipid-lowering Medication Adherence</title>
        <description>Measured by Morisky Medication taking questionnaire (self-reported). Scores range from 0-4, with 0 being least adherent and 4 being most adherent</description>
        <time_frame>6 months</time_frame>
        <population>One participant in TI did not answer all of the questions on this assessment, so his score could not be computed and therefore he is not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tailored Intervention (TI)</title>
            <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
          </group>
          <group group_id="O2">
            <title>Attention Placebo (AP)</title>
            <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
          </group>
        </group_list>
        <measure>
          <title>Antihypertensive/ Lipid-lowering Medication Adherence</title>
          <description>Measured by Morisky Medication taking questionnaire (self-reported). Scores range from 0-4, with 0 being least adherent and 4 being most adherent</description>
          <population>One participant in TI did not answer all of the questions on this assessment, so his score could not be computed and therefore he is not included in this analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.76"/>
                    <measurement group_id="O2" value="3.43" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tailored Intervention (TI)</title>
          <description>Tailored phone intervention targeting diet, exercise, and medication adherence based on the transtheoretical model</description>
        </group>
        <group group_id="E2">
          <title>Attention Placebo (AP)</title>
          <description>General phone counseling about health topics unrelated to stroke risk factors (e.g., pain, colorectal cancer screening)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Bypass Graft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Broken bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Torn Ligament</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bone/Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Friedberg, Ph.D.</name_or_title>
      <organization>VA New York Harbor Healthcare System</organization>
      <phone>212-951-3314</phone>
      <email>jennifer.friedberg@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

